0000950170-24-097322.txt : 20240814 0000950170-24-097322.hdr.sgml : 20240814 20240814200004 ACCESSION NUMBER: 0000950170-24-097322 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240812 FILED AS OF DATE: 20240814 DATE AS OF CHANGE: 20240814 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Izumi Raquel E. CENTRAL INDEX KEY: 0001832553 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39244 FILM NUMBER: 241210229 MAIL ADDRESS: STREET 1: 4500 GREAT AMERICA PKWY STREET 2: STE. 100 #29 CITY: SANTA CLARA STATE: CA ZIP: 95054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vincerx Pharma, Inc. CENTRAL INDEX KEY: 0001796129 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 833197402 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 260 SHERIDAN AVENUE STREET 2: SUITE 400 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-800-6676 MAIL ADDRESS: STREET 1: 260 SHERIDAN AVENUE STREET 2: SUITE 400 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: Vincera Pharma, Inc. DATE OF NAME CHANGE: 20201223 FORMER COMPANY: FORMER CONFORMED NAME: LifeSci Acquisition Corp. DATE OF NAME CHANGE: 20191206 4 1 ownership.xml 4 X0508 4 2024-08-12 false 0001796129 Vincerx Pharma, Inc. VINC 0001832553 Izumi Raquel E. 260 SHERIDAN AVENUE, SUITE 400 PALO ALTO CA 94306 true true false false See Remarks false Stock Option (right to buy) 6.26 2024-08-12 4 D false 76500 D 2032-02-13 Common Stock 76500 0 D Stock Option (right to buy) 0.55 2024-08-12 4 A false 76500 A 2032-02-13 Common Stock 76500 76500 D Stock Option (right to buy) 1.71 2024-08-12 4 D false 60000 D 2032-08-24 Common Stock 60000 0 D Stock Option (right to buy) 0.55 2024-08-12 4 A false 60000 A 2032-08-24 Common Stock 60000 60000 D Stock Option (right to buy) 0.82 2024-08-12 4 D false 60000 D 2032-11-14 Common Stock 60000 0 D Stock Option (right to buy) 0.55 2024-08-12 4 A false 60000 A 2032-11-14 Common Stock 60000 60000 D Stock Option (right to buy) 1.17 2024-08-12 4 D false 90000 D 2033-02-14 Common Stock 90000 0 D Stock Option (right to buy) 0.55 2024-08-12 4 A false 90000 A 2033-02-14 Common Stock 90000 90000 D Stock Option (right to buy) 7.38 2024-08-12 4 D false 123750 D 2034-03-06 Common Stock 123750 0 D Stock Option (right to buy) 0.55 2024-08-12 4 A false 123750 A 2034-03-06 Common Stock 123750 123750 D Stock Option (right to buy) 7.38 2024-08-12 4 D false 41250 D 2034-03-06 Common Stock 41250 0 D Stock Option (right to buy) 0.55 2024-08-12 4 A false 41250 A 2034-03-06 Common Stock 41250 165000 D On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the "Repriced Options"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the "Repricing"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors. Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter. Option vests in twenty-four equal monthly installments starting from August 25, 2022. Option vests in twenty-four equal monthly installments starting from November 15, 2022. Option vests in twenty-four equal monthly installments starting from February 15, 2023. One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter. President and Chief Operations Officer By: /s/ Alexander A. Seelenberger, attorney-in-fact 2024-08-14